Bayer Makes Tentative Deal in Drug-Price Probe

Article

WASHINGTON - In the first settlement of a state and federal investigation of drug-industry pricing practices, a US unit of Bayer AG has tentatively agreed to pay $14 million to resolve allegations that it caused Medicaid to overpay for its drugs. Bayer, which has confirmed a settlement, has not admitted wrongdoing. The settlement requires that the company report more accurate price information for all of its drugs to state and federal regulators. In addition, the company must cooperate with continuing investigation.

More than 20 drug companies are under current investigation, including Abbott Laboratories, Bristol-Myers Squibb Co., Glaxo Wellcome PLC's US unit, and SmithKline Beecham PLC. All companies have denied any wrongdoing. For more information visit www.hcfa.gov/medicaid.

Recent Videos
Anthony Bondon CRCST, CHL, BSM, AAS, SME, LSSYB
Deannard Esnard, CRCST, CIS, CER, CHL, CFER, CQUIA
Kevin Bush, Jr, DHSc, EdD, MSHA, MA, MS, FACHE
Vatsala Rangachar Srinivasa, MPH
Sarah Vinson, MBA, CRCST
Kevin Anderson, MBA, BS, CRCST, Senior Manager, Commercial Education Services, Heatlthmark, a Getinge Company
Damien Berg, BA, BS, CRCST, AAMIF, is the vice president of strategic initiatives for the HSPA.
Annet Adegboyega, DNP, MSN, BSN, RN, CNOR; Mihyun "Rose" Jang, MSN, MPH, BSN, RN, CNOR; and Renilda Tijones, MSN, BSN, RN, CNOR.
Roundtable of Vet IPs (Adobe Stock)
APIC 2025 President Carol McLay, DrPH, MPH, RN, CIC FAPIC   (Image credit: APIC)
Related Content